A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer
Bogang Wu, Win Thant, Elena Bitman, T. Liu, Jie Liu, Eleftherios I. Paschalis, Bidish K. Patel, Cole Nawrocki, Katherine H. Xu, Linda T. Nieman, David Tsai Ting, Bruna de Gois Macedo, Yang Cheng, Kevin Jiang, Fengfei Sun, , Leif William Ellisen
This study identifies TROP2 as a regulator of tight junction-mediated immune exclusion in TNBC, showing that targeting TROP2 enhances anti-PD1 therapy response.
Journal for ImmunoTherapy of Cancer · Apr 1, 2026Peer-reviewedCancer Biology